Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Streptococcal Infections | 9 | 2020 | 240 | 3.400 |
Why?
|
| Prenatal Care | 7 | 2024 | 348 | 3.150 |
Why?
|
| Pregnancy Complications, Infectious | 12 | 2023 | 455 | 2.840 |
Why?
|
| Streptococcus agalactiae | 8 | 2020 | 99 | 2.530 |
Why?
|
| Gynecology | 4 | 2022 | 124 | 2.370 |
Why?
|
| Obstetrics | 5 | 2022 | 238 | 2.290 |
Why?
|
| Antibiotic Prophylaxis | 5 | 2020 | 119 | 1.890 |
Why?
|
| Pregnancy | 43 | 2024 | 7208 | 1.670 |
Why?
|
| Chorioamnionitis | 2 | 2021 | 42 | 1.480 |
Why?
|
| Fetal Membranes, Premature Rupture | 2 | 2021 | 60 | 1.430 |
Why?
|
| Version, Fetal | 2 | 2020 | 6 | 1.410 |
Why?
|
| Social Media | 2 | 2022 | 105 | 1.220 |
Why?
|
| Cesarean Section | 7 | 2023 | 389 | 0.950 |
Why?
|
| Periodicals as Topic | 2 | 2019 | 197 | 0.910 |
Why?
|
| Pregnancy Trimester, Third | 4 | 2020 | 120 | 0.870 |
Why?
|
| Delphi Technique | 2 | 2024 | 209 | 0.840 |
Why?
|
| Labor Stage, Second | 1 | 2023 | 16 | 0.830 |
Why?
|
| Vaginal Birth after Cesarean | 2 | 2020 | 23 | 0.800 |
Why?
|
| Female | 51 | 2024 | 66781 | 0.800 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2022 | 27 | 0.770 |
Why?
|
| Neonatal Sepsis | 1 | 2022 | 32 | 0.770 |
Why?
|
| Surgical Mesh | 1 | 2022 | 61 | 0.770 |
Why?
|
| Endometritis | 1 | 2021 | 8 | 0.770 |
Why?
|
| Breech Presentation | 2 | 2020 | 20 | 0.750 |
Why?
|
| Penicillins | 2 | 2020 | 154 | 0.740 |
Why?
|
| Venous Thromboembolism | 2 | 2020 | 167 | 0.700 |
Why?
|
| Humans | 62 | 2024 | 125128 | 0.690 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2023 | 616 | 0.690 |
Why?
|
| Peripartum Period | 1 | 2020 | 28 | 0.680 |
Why?
|
| Prenatal Diagnosis | 2 | 2018 | 598 | 0.650 |
Why?
|
| Vulvar Lichen Sclerosus | 1 | 2019 | 6 | 0.650 |
Why?
|
| Sexism | 1 | 2019 | 36 | 0.640 |
Why?
|
| Genitalia, Female | 1 | 2019 | 47 | 0.620 |
Why?
|
| Platelet Count | 1 | 2019 | 136 | 0.620 |
Why?
|
| Drug Hypersensitivity | 1 | 2020 | 95 | 0.610 |
Why?
|
| Cervix Uteri | 2 | 2017 | 64 | 0.610 |
Why?
|
| Liability, Legal | 1 | 2018 | 44 | 0.600 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2019 | 79 | 0.600 |
Why?
|
| Lacerations | 1 | 2019 | 33 | 0.600 |
Why?
|
| Fetal Death | 1 | 2018 | 112 | 0.590 |
Why?
|
| Anti-Bacterial Agents | 4 | 2020 | 2431 | 0.590 |
Why?
|
| Patient Preference | 1 | 2019 | 118 | 0.590 |
Why?
|
| Stillbirth | 1 | 2018 | 79 | 0.590 |
Why?
|
| Delivery, Obstetric | 3 | 2022 | 252 | 0.550 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2020 | 241 | 0.540 |
Why?
|
| Parturition | 1 | 2017 | 63 | 0.530 |
Why?
|
| Betacoronavirus | 1 | 2020 | 289 | 0.530 |
Why?
|
| Bias | 1 | 2017 | 133 | 0.510 |
Why?
|
| Pandemics | 2 | 2022 | 1108 | 0.510 |
Why?
|
| Obstetric Labor Complications | 3 | 2007 | 93 | 0.510 |
Why?
|
| Infant, Newborn | 13 | 2023 | 8232 | 0.500 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 233 | 0.500 |
Why?
|
| Carrier State | 1 | 2015 | 76 | 0.490 |
Why?
|
| Telemedicine | 2 | 2021 | 436 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 359 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 1117 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.460 |
Why?
|
| Physicians | 1 | 2019 | 586 | 0.410 |
Why?
|
| Pregnancy Outcome | 6 | 2024 | 592 | 0.400 |
Why?
|
| United States | 7 | 2024 | 10891 | 0.390 |
Why?
|
| Internship and Residency | 1 | 2022 | 1144 | 0.380 |
Why?
|
| Biomedical Research | 1 | 2017 | 519 | 0.360 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 2913 | 0.360 |
Why?
|
| Cerclage, Cervical | 2 | 2007 | 12 | 0.340 |
Why?
|
| Pregnancy Complications | 4 | 2021 | 514 | 0.340 |
Why?
|
| Sepsis | 1 | 2014 | 481 | 0.340 |
Why?
|
| Erythromycin | 2 | 2021 | 20 | 0.320 |
Why?
|
| Retrospective Studies | 14 | 2023 | 16348 | 0.310 |
Why?
|
| Adult | 18 | 2024 | 29611 | 0.310 |
Why?
|
| Anticoagulants | 2 | 2020 | 593 | 0.300 |
Why?
|
| Genetic Testing | 1 | 2014 | 1004 | 0.290 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 510 | 0.280 |
Why?
|
| Uterus | 2 | 2007 | 569 | 0.280 |
Why?
|
| Hospitals, Community | 2 | 2007 | 55 | 0.280 |
Why?
|
| Gestational Age | 3 | 2023 | 1167 | 0.280 |
Why?
|
| Constriction, Pathologic | 2 | 2007 | 240 | 0.280 |
Why?
|
| Hospitals, University | 1 | 2007 | 97 | 0.270 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2006 | 3 | 0.260 |
Why?
|
| Prothrombin Time | 1 | 2006 | 36 | 0.250 |
Why?
|
| Fluconazole | 1 | 2006 | 47 | 0.250 |
Why?
|
| Cerebral Palsy | 1 | 2007 | 80 | 0.240 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 1997 | 104 | 0.240 |
Why?
|
| Warfarin | 1 | 2006 | 119 | 0.230 |
Why?
|
| Vagina | 3 | 2021 | 185 | 0.220 |
Why?
|
| Appointments and Schedules | 1 | 2024 | 49 | 0.220 |
Why?
|
| Decision Making | 2 | 2020 | 656 | 0.210 |
Why?
|
| Fetal Viability | 1 | 2023 | 29 | 0.210 |
Why?
|
| Antifungal Agents | 1 | 2006 | 291 | 0.210 |
Why?
|
| Labor Stage, First | 1 | 2023 | 7 | 0.210 |
Why?
|
| Parity | 1 | 2023 | 78 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1271 | 0.200 |
Why?
|
| China | 1 | 2023 | 246 | 0.200 |
Why?
|
| Surgical Instruments | 1 | 2021 | 56 | 0.190 |
Why?
|
| Azithromycin | 1 | 2021 | 43 | 0.190 |
Why?
|
| Postpartum Hemorrhage | 1 | 2022 | 97 | 0.190 |
Why?
|
| Pain, Postoperative | 2 | 2021 | 258 | 0.180 |
Why?
|
| Pregnancy, Multiple | 3 | 2014 | 47 | 0.180 |
Why?
|
| Urinary Retention | 1 | 2021 | 18 | 0.180 |
Why?
|
| Morbidity | 1 | 2021 | 249 | 0.180 |
Why?
|
| Respiratory Insufficiency | 1 | 2023 | 225 | 0.180 |
Why?
|
| Hysterectomy | 1 | 2022 | 187 | 0.170 |
Why?
|
| Consensus | 1 | 2024 | 641 | 0.170 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 175 | 0.170 |
Why?
|
| Desogestrel | 1 | 2020 | 7 | 0.170 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2021 | 60 | 0.170 |
Why?
|
| Simulation Training | 1 | 2022 | 138 | 0.170 |
Why?
|
| Contraceptive Agents, Female | 1 | 2020 | 30 | 0.170 |
Why?
|
| Contraception | 1 | 2020 | 57 | 0.160 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 28 | 0.160 |
Why?
|
| Uterine Contraction | 2 | 1997 | 28 | 0.160 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 78 | 0.160 |
Why?
|
| Birth Injuries | 1 | 1999 | 22 | 0.160 |
Why?
|
| Choice Behavior | 1 | 2019 | 132 | 0.150 |
Why?
|
| Endometriosis | 1 | 2021 | 170 | 0.150 |
Why?
|
| Heart Rate, Fetal | 1 | 2018 | 62 | 0.150 |
Why?
|
| Twins | 2 | 2014 | 69 | 0.150 |
Why?
|
| Middle Aged | 5 | 2021 | 26920 | 0.150 |
Why?
|
| Maternal Age | 1 | 2018 | 134 | 0.150 |
Why?
|
| Probability | 1 | 2018 | 320 | 0.150 |
Why?
|
| Overweight | 1 | 2021 | 364 | 0.150 |
Why?
|
| Nausea | 1 | 2018 | 86 | 0.150 |
Why?
|
| Reference Values | 1 | 2019 | 718 | 0.140 |
Why?
|
| Rectus Abdominis | 1 | 1997 | 8 | 0.140 |
Why?
|
| Anesthesia | 1 | 2020 | 207 | 0.140 |
Why?
|
| Vomiting | 1 | 2018 | 105 | 0.140 |
Why?
|
| Abruptio Placentae | 1 | 1997 | 16 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2022 | 3073 | 0.140 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 207 | 0.140 |
Why?
|
| Heart Diseases | 2 | 2019 | 495 | 0.140 |
Why?
|
| Dystocia | 1 | 1997 | 23 | 0.130 |
Why?
|
| Betamethasone | 1 | 1996 | 13 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2020 | 385 | 0.130 |
Why?
|
| Muscular Diseases | 1 | 1997 | 103 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2022 | 12391 | 0.130 |
Why?
|
| Hematoma | 1 | 1997 | 93 | 0.130 |
Why?
|
| Terbutaline | 1 | 1996 | 6 | 0.130 |
Why?
|
| Tocolytic Agents | 1 | 1996 | 12 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 474 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2021 | 6150 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2020 | 697 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 634 | 0.130 |
Why?
|
| Chlamydia trachomatis | 1 | 1995 | 25 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 612 | 0.130 |
Why?
|
| Gastroplasty | 1 | 1995 | 11 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2015 | 1259 | 0.130 |
Why?
|
| Diseases in Twins | 1 | 1996 | 94 | 0.120 |
Why?
|
| Coronary Aneurysm | 1 | 1996 | 33 | 0.120 |
Why?
|
| Obstetric Labor, Premature | 1 | 1996 | 85 | 0.120 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 1996 | 81 | 0.120 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 1996 | 46 | 0.120 |
Why?
|
| Chlamydia Infections | 1 | 1995 | 49 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3300 | 0.120 |
Why?
|
| Amoxicillin | 1 | 1995 | 121 | 0.120 |
Why?
|
| Recurrence | 2 | 2015 | 1420 | 0.120 |
Why?
|
| Heart Transplantation | 2 | 2012 | 862 | 0.120 |
Why?
|
| Term Birth | 1 | 2014 | 32 | 0.120 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 1994 | 28 | 0.110 |
Why?
|
| Herpes Genitalis | 1 | 1994 | 11 | 0.110 |
Why?
|
| Thromboembolism | 1 | 1995 | 89 | 0.110 |
Why?
|
| Age Factors | 2 | 2019 | 2823 | 0.110 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1994 | 113 | 0.110 |
Why?
|
| Quality of Life | 1 | 2024 | 1934 | 0.110 |
Why?
|
| Risk Factors | 4 | 2021 | 10314 | 0.110 |
Why?
|
| Aneuploidy | 1 | 2014 | 152 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 1996 | 383 | 0.110 |
Why?
|
| Fibrinolytic Agents | 1 | 1995 | 205 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1995 | 227 | 0.110 |
Why?
|
| Catheterization, Central Venous | 1 | 1994 | 131 | 0.100 |
Why?
|
| Forecasting | 1 | 2014 | 351 | 0.100 |
Why?
|
| Heart-Assist Devices | 2 | 2012 | 1026 | 0.100 |
Why?
|
| Bacteriological Techniques | 1 | 2013 | 87 | 0.100 |
Why?
|
| Heart Atria | 1 | 1994 | 316 | 0.100 |
Why?
|
| Heart Failure, Systolic | 1 | 2012 | 34 | 0.100 |
Why?
|
| Dilatation | 2 | 2023 | 67 | 0.090 |
Why?
|
| Postpartum Period | 2 | 2023 | 216 | 0.080 |
Why?
|
| Mass Screening | 1 | 2015 | 784 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 3724 | 0.080 |
Why?
|
| Thrombosis | 1 | 1994 | 526 | 0.080 |
Why?
|
| Myocarditis | 1 | 2011 | 129 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 162 | 0.080 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2011 | 213 | 0.080 |
Why?
|
| Young Adult | 2 | 2020 | 9049 | 0.080 |
Why?
|
| Colony Count, Microbial | 1 | 2008 | 89 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 1996 | 1050 | 0.070 |
Why?
|
| Cervical Length Measurement | 1 | 2007 | 5 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 1897 | 0.070 |
Why?
|
| Uterine Cervical Incompetence | 1 | 2007 | 6 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2009 | 290 | 0.070 |
Why?
|
| Elective Surgical Procedures | 1 | 2007 | 160 | 0.060 |
Why?
|
| Aged | 2 | 2021 | 19870 | 0.060 |
Why?
|
| Adolescent | 3 | 2019 | 19361 | 0.060 |
Why?
|
| Texas | 2 | 2007 | 3588 | 0.060 |
Why?
|
| Logistic Models | 2 | 2020 | 1809 | 0.050 |
Why?
|
| Male | 5 | 2019 | 61501 | 0.050 |
Why?
|
| Patient Selection | 1 | 2007 | 698 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 92 | 0.050 |
Why?
|
| Michigan | 1 | 2021 | 42 | 0.050 |
Why?
|
| Prevalence | 1 | 2008 | 2458 | 0.050 |
Why?
|
| Pelvic Pain | 1 | 2021 | 23 | 0.050 |
Why?
|
| Curettage | 1 | 2020 | 6 | 0.040 |
Why?
|
| Drug Implants | 1 | 2020 | 42 | 0.040 |
Why?
|
| Puerperal Disorders | 1 | 2020 | 45 | 0.040 |
Why?
|
| Postnatal Care | 1 | 2020 | 51 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 126 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2021 | 345 | 0.040 |
Why?
|
| Birth Weight | 1 | 2021 | 345 | 0.040 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 1825 | 0.040 |
Why?
|
| Incidence | 2 | 1997 | 3146 | 0.040 |
Why?
|
| Weight Gain | 1 | 2021 | 400 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2023 | 941 | 0.040 |
Why?
|
| Abdomen, Acute | 1 | 1997 | 14 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 404 | 0.030 |
Why?
|
| Trial of Labor | 1 | 1997 | 21 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 1997 | 286 | 0.030 |
Why?
|
| Contraindications | 1 | 1996 | 78 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2021 | 971 | 0.030 |
Why?
|
| Arginine | 1 | 2018 | 336 | 0.030 |
Why?
|
| Time Factors | 1 | 2006 | 6329 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1178 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1995 | 81 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 1565 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 1995 | 139 | 0.030 |
Why?
|
| Cesarean Section, Repeat | 1 | 1994 | 8 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2023 | 4811 | 0.030 |
Why?
|
| History, 20th Century | 1 | 1995 | 381 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 1995 | 185 | 0.030 |
Why?
|
| Rectum | 1 | 2013 | 99 | 0.020 |
Why?
|
| Reoperation | 1 | 1995 | 833 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1995 | 470 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 3465 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 1995 | 1100 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2011 | 31 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2013 | 389 | 0.020 |
Why?
|
| Infant, Premature | 1 | 1996 | 829 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2012 | 228 | 0.020 |
Why?
|
| North America | 1 | 2011 | 241 | 0.020 |
Why?
|
| Obesity | 1 | 2021 | 2248 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 1056 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2012 | 681 | 0.020 |
Why?
|
| Shock, Cardiogenic | 1 | 2011 | 192 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 757 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2057 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 2062 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2885 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2011 | 499 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2012 | 14027 | 0.020 |
Why?
|
| Premature Birth | 1 | 2007 | 387 | 0.010 |
Why?
|
| Child | 2 | 2012 | 24424 | 0.010 |
Why?
|
| Infant | 1 | 2011 | 12515 | 0.010 |
Why?
|